Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12047052 | 0.90 | CYP1A2 (0.31) | CYP1A2 | |
| SCHEMBL23334387 | 0.89 | — | — | |
| SCHEMBL24857108 | 0.85 | — | — | |
| SCHEMBL12921212 | 0.83 | — | — | |
| SCHEMBL18542740 | 0.83 | CXCR4 (0.33) | — | |
| SCHEMBL10157092 | 0.83 | — | — | |
| SCHEMBL13763266 | 0.83 | — | — | |
| SCHEMBL12733693 | 0.79 | CYP1A2 (0.34) | CYP1A2 | |
| SCHEMBL8559039 | 0.78 | — | — | |
| SCHEMBL23083514 | 0.78 | KDM4E (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013177284-A1 | HAFNIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | claimed |
| WO-2013177269-A2 | ZIRCONIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | claimed |
| WO-2013177292-A1 | TITANIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | claimed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230381150-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-11-30 | — | — | US | disclosed |
| US-20230381149-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-11-30 | — | — | US | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11760775-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. | 2023-09-19 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-20110166122-A1 | SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2011-07-07 | — | — | US | disclosed |
| US-20110166122-A1 | SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2011-07-07 | — | — | US | disclosed |
| US-20110129440-A1 | Heterocyclic Urea and Thiourea Derivatives and Methods of Use Thereof | SCHERING CORPORATION | 2011-06-02 | — | — | US | disclosed |
| US-20100197662-A1 | HETEROCYCLIC COMPOUND HAVING TYPE I 11 BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20090087409-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-04-02 | — | — | US | disclosed |
| WO-2004048368-A2 | HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090087409-A1 | Viral Polymerase Inhibitors | NR2C2, NR4A1, MED25 | CYP1A2 218/4885OPRM1 55/4885 |
| US-20230381150-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CYP1A2 33/4885OPRM1 303/4885 |
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | CYP1A2 3111/4885OPRM1 4800/4885 |
| US-20110129440-A1 | Heterocyclic Urea and Thiourea Derivatives and Methods of Use Thereof | MTOR, PRKDC, PRKACA | CYP1A2 2075/4885OPRM1 4511/4885 |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | PDXK, DTYMK, TNNI3K | CYP1A2 2809/4885OPRM1 3096/4885 |
| US-20100197662-A1 | HETEROCYCLIC COMPOUND HAVING TYPE I 11 BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | HSD11B1, HSD3B1, HSD11B2 | CYP1A2 198/4885OPRM1 1479/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | CYP1A2 3908/4885OPRM1 4204/4885 |
| US-20110166122-A1 | SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | NTRK1, NTRK3, NTRK2 | CYP1A2 1387/4885OPRM1 2018/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | CYP1A2 73/4885OPRM1 3594/4885 |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | ITGA2B, ITGB6, ITGB1 | CYP1A2 4799/4885OPRM1 3415/4885 |
| US-20230381149-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CYP1A2 33/4885OPRM1 303/4885 |
| US-11760775-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | CYP1A2 4423/4885OPRM1 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.